NASOCOMIAL INFECTOIONS IN CANCER PATIENTS: PROBLEM OF GRAM-NEGATIVE BACTERIAL RESISTANCE

The problem of prevention and treatment of hospital-acquired (nosocomial) infections excites progressive minds of humanity for centuries. The risk and incidence of nosocomial infections are constantly increasing. It becomes harder and harder to fight with them. Special attention is paid to nosocomial infections caused by resistant gram-negative organisms. This is a problem for clinics in all countries. National programs for the prevention of the development and spread of resistant strains have been developed in the majority of countries. Infectious complications develop more frequently and more severe in cancer patients than in non-cancer patients. Infectious complications in these patients are mainly associated with hospital-acquired infections. Complications caused by resistant gram-negative microorganisms, such as P. aeruginosa, A. baumannii and K. rneumoniae are especially dangerous complications. The clinical management of these patients is difficult and requires teamwork of microbiologists and clinicians.

cancer patients, P. aeruginosa, A. baumannii, K. рneumoniaе, resistant gram-negative microorganisms, nosocomial infections, treatment of infections, antibiotics

1. Grigorievskaya Z.V. Treatment strategy for nosocomial infections caused by resistant microorganisms in cancer clinics. [Doctoral thesis]. [Moscow]; 2015. 252 p. [in Russian]

2. Grigorievskaya Z.V. Problem of hospital-acquired infections in cancer clinics. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2013; 24 (3–4): 46–49. [in Russian]

3. Grigorievskaya Z.V., Petukhova I.N., Dyakova S.A., Dmitrieva N.V. Infectious infections caused by Acinetobacter baumanii in cancer patients. Siberial Journal of Oncology. 2011; 6: 14–18. [in Russian]

4. Sidorenko S.V., Rezvan S.P., Eremina L.V., Polikarpova S.V., Karbak B.I., Menshikova Е.D. Etiology of severe hospital-acquired infections in intensive care departments and antibiotic resistance among pathogens. Antibiotics and chemotherapy. 2005; 2–3 (50): 33–41. [in Russian]

5. Sidorenko S.V., Tishkov V.I. Molecular bases of resistance to antibiotics. Advances in biological chemistry. 2004; 44: 263–306. [in Russian]

6. Dent L.L., Marshall D.R., Pratap S. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis. 2010 Jul 7; 10: 196. doi: 10.1186/1471-2334-10-196.

7. Esposito S., Leon S. Antimicrobial treatment of infections in intensive care units. Role of infectious disease. Int J Antimicrob Agents. 2007; 29: 494–500.

8. WHO Global Strategy for Containment of Antimicrobial Resistance. World Health Organization. Geneva. 2001; 90.

9. Center for Disease Control and Prevention [cited 01.11.2016]. Available from: www.cdc.gov.

10. Belotserkovsky B.Z., Gelfand Е.B., Popov T.V., Krasnov V.G. Hospital-acquired microorganisms. Infections in surgery. 2008; 1 (6): 18–24. [in Russian]

11. Davydov М.I., Dmitrieva N.V. Infections in oncology. Moscow. 2009; 472 p. [in Russian]

12. Bowers D.R., Liew Y.X., Lye D.C., Kwa A.L., Hsu L.Y., Tam V.H. Outcomes of appropriate empiric combination versus monotherapy for P. aeruginosa bacteremia. Antimicrob Agents Chemother. 2013 Mar; 57 (3): 1270–4. doi: 10.1128/AAC.02235-12.

13. Mandel G.L. Principles and Practice of Infections Diseases. 16th ed. Elsevier Churchill Livingstone, 2010; 4320 р.

14. Wang C.Y., Jermg J.S., Cheng K.Y. Pandrug-resistant Pseudomonas aeruginosa among hospitalized patients: clinical features, risk-factors and outcomes. Clinical Microbiology Infection. 2006; 12: 63–64.

15. Rudnov V.А., Zubarev А.S. Infections caused by P. aeruginosa и Acinetobacter spp in intensive care unit. Consilium medicum. 2008; 1: 37 44. [in Russian]

16. Gootz T.D., Marra A. Acinetobacter baumannii: An Emerging Multidrug-resistant Threat: Overview of Antibiotic-resistance mechanism. Expert Review of Anti-infective Therapy. 2008; 6 (3): 309–325.

17. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008 Jul; 21 (3): 538–82. doi: 10.1128/CMR.00058-07.

18. Abbott I., Cerqueira G.M., Bhuiyan S., Peleg A.Y. Carbapenem Resistance in Acinetobacter baumannii. Expert Rev Anti Infect Ther. 2013 Apr; 11 (4): 395–409. doi: 10.1586/eri.13.21.

19. Adams M. D., Nickel G.C., Bajaksouzian S., Lavender H., Murthy A.R., Jacobs M.R., Bonomo R.A. Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System. Antimicrob Agents Chemother. 2009 Sep; 53 (9): 3628–34. doi: 10.1128/AAC.00284-09.

20. Bonomo R.A., Szabo D. Mechanisms of Multidrug Resistance in Acinetobacter species and Pseudomonas aeruginosa. Clinical Infectious Diseases. 2006; 43 (2): 49–56. doi: 10.1086/504477.

21. Cai Y., Chai D., Wang R., Liang B., Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012 Jul; 67 (7): 1607–15. doi: 10.1093/jac/dks084.

22. Chiu C.H., Lee H.Y., Tseng L.Y.,Chen C.L.,Chia J.H., Su L.H., Liu S.Y. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan. Int J Antimicrob Agents. 2010 Apr; 35 (4): 382–6. doi: 10.1016/j. ijantimicag.2009.12.009

23. Gordon N.C., Wareham D.W. Multidrug-resistant Acinetobacter baumannii: mechanisms and resistance. Int J Antimicrob Agents. 2010; 35 (3): 219–22.

24. Kim Y.J., Hong K.W., Wie S.H., Park Y.J., Jeong H., Kan M.W. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect. 2012 Jan; 140 (1): 137–45. doi: 10.1017/S0950268811000744.

25. Lee H.Y., Chen C.L., Wang S.B., Su L.H., Chen S.H., Liu S.Y., Wu T.L., Lin T.Y., Chiu C.H. Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications. Int J Antimicrob Agents. 2011 Apr; 37 (4): 302–8. doi: 10.1016/j.ijantimicag.2010.12.015

26. Dmitrieva N.V., Grigorievskaya Z.V., Dyakova S.А., Klyuchnikova I.А., Petukhova I.N. Therapeutic strategies against infections caused by multiresistant Acinetobacter baumanii. Siberian Journal of Oncology. 2012; 4: 11–19. [in Russian]

27. Falagas M.E., Bliziotis I.A., Siempos I.I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Critical Care. 2006; 10: 48.

28. Monaghan K. Strategic Implications of Global Health. National intelligence council Washington DC. 2008; ICA-2008-10D.

29. Poirel L., Potron A., Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012 Jul; 67 (7): 1597–606. doi: 10.1093/jac/dks121.

30. Guidance for Control of Carbapenem-Resistant Enterobacteriaceae [cited 01.11.2016).]. Available from: www.cdc.gov.

31. Poirel L., Schrenzel J., Cherkaoui A. , S. Bernabeu, G. Renzi, P. Nordmann. Molecular analysis of NDM-1-producing enterobacterial isolates from Geneva, Switzerland. J Antimicrob Chemother. 2011 Aug; 66 (8): 1730–3. doi: 10.1093/jac/dkr174.

32. Shabanova V.V., Krasnova М.V., Bozhkova S.А., Ageevets V.А., Lazareva I.V., Rukina А.N., Sidorenko S.V. The first case of detection of Klebsiella Pneumoniae ST147 in Russia, producing NDM-1 carbapenemases in trauma and orthopedic hospital. Traumatology and Orthopedics. 2015; 2 (76); 90–98. [in Russian]

33. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017.

34. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. American Journal of Health-System Pharmacy. 2013; 70: 195–283.

35. Snitkin E.S., Zelazny A.M., Thomas P.J., Stock F., NISC Comparative Program Group, Henderson D.K., Palmore T.N., Seqre J.A. Tracking a Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae with Whole-Genome Sequencing. Sci Transl Med. 2012 Aug 22; 4 (148): 148ra116. doi: 10.1126/scitranslmed.3004129.

36. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C.G., Irfan S., Krishnan P., Kumar A.V., Maharjan S., Mushtaq S., Noorie T., Paterson D.L., Pearson A., Perry C., Pike R., Rao B., Ray U., Sarma J.B., Sharma M., Sheridan E., Thirunarayan M.A., Turton J., Upadhyay S., Warner M., Welfare W., Livermore D.M., Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010 Sep; 10(9): 597 602. doi: 10.1016/S1473-3099(10)70143-2.

37. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., Walsh T.R. Characterization of a new metallo-beta-lactamase gene, blandm-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009; 53: 5046–54.

38. Chen Y., Lin A., Siu L.K., Koh T.H. Sequence of Closely Related Plasmids Encoding bla (NDM-1) in Two Unrelated Klebsiella pneumoniae Isolates in Singapore. PLoS One. 2012; 7 (11): e48737. doi: 10.1371/ journal.pone.0048737.

39. Kallen A., Guh A. United states centers for disease control and prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae. Eurosurveillance. 2012; 17 (Issue 26): 27.

40. Grigorievskaya Z.V., Petukhova I.N., Dmitrieva N.V. An outbreak of nosocomial infections caused by multiresistant (MDR) strains of K.pneumoniae. Siberian Journal of Oncology. 2014; 2: 5–8. [in Russian]